ANT308
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2871680-36-1
- Formule: C156H261N47O40S
- Masse moléculaire:3467.10
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PACAP Receptor
More
Activité biologique
ANT308 (1-10 μM, 48 h) significantly enhances CD69 and Ki67 expressions in CD4+ and CD8+ T cells[1].
ANT308 (0.1-10 μM, 72 h) reduces the viability of B16F10 and HT-144 cells dose-dependently[2].
ANT308 (10 μM, 72 h) decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells[2].
ANT308 (10 μM, 8 h) significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines[2].
ANT308 (72 h) reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B16F10 and HT-144 cells
-
Concentration:0.1, 1, 5 and 10 μM
-
Incubation Time:72 h
-
Result:Decreased the numbers of viable B16F10 and HT-144 cells by around 46% and 27%, respectively, compared to control cultures with 5 μM twice daily.
-
Cell Line:B16LS9 and Mel 290 cells
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Increased percentages of apoptotic cells.
-
Cell Line:B16LS9 and Mel 290 cells
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Decreased cells in the S phase.
-
Cell Line:B16LS9, B16F10, Mel 290 cells, HT-144 cells
-
Concentration:10 μM
-
Incubation Time:8 h
-
Result:Significantly inhibited cell migration in the B16LS9, Mel290, and HT-144 cell lines
ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:P815 cells induced AML model established in DBA/2j (H2Kd) mice[1]
-
Dosage:6 nmol
-
Administration:Subcutaneous injection (s.c.), once daily for 10-14 weeks
-
Result:Significantly prolonged the survival period of mice and reduced the tumor burden.
-
Animal Model:B16LS9 induced UVM model and B16LS9 or B16LS9 induced subcutaneous melanoma model established in female C57BL6/J mice (8-10 weeks) and NRG (NOD Rag gamma) mice (10-11 months old)[2]
-
Dosage:100 μg/100 μL PBS
-
Administration:Subcutaneous injection (s.c.), twice a day for 10 days
-
Result:Significantly reduced the number of liver metastases. Reduced MCAM, but had no significant effect on N-cadherin expression. had no significant effect on subcutaneous tumor volume.
Chemical Information
-
CAS No. 2871680-36-1
-
Masse moléculaire 3467.10
-
Formule C156H261N47O40S
-
SMILES
O=C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N
-
Sequence
Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Ser-Asp-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Leu-Ile-Leu-Asn
-
Sequence Shortening
KPRRPYTSDYTRLRKQMAVKKYLNLILN
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ANT308 Related Classifications
HY-P11288 Related Classifications
Powered by Bioz